Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 85-92

  Jacobson, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; INFECTION RISK; NEUTROPENIA; PRIORITY JOURNAL; RETINITIS;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0029911805     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_10     Document Type: Conference Paper

References (30)

1. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988;10:S490-4.
2. Sullivan V, Talarico CL, Stanat SC, Davis M et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162.
3. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160.
4. Oberg B. Antiviral efffects of phosphonoformate. Pharmac Ther 1983;19:387-415.
5. Verheyden JPH. Evolution of therapy for cytomegalovirus infections. Rev Infect Dis 1988;10:S477-89.
6. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(I,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;152:833-4.
7. Akesson-Johansson A, Lernestedt JO, Ringden O, Lonnqvist B, Wahren B. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Bone Marrow Transplant 1986;1:215-20.
8. Sandstrom EG, Byington RE, Kaplan JE, Hirsch MS. Inhibition of human T cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1985;1:1480-2.
9. Sommadossi JP, Bevan R, Long T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988;10:S507-14.
10. Sjovall J, Karlsson A, Ogenstad S, Sandstrom E, Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988;44:65-73.
11. Smee DR, Boehme R, Chernow M et al. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985;34:1049-56.
12. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-805.
13. Walmsley SL, Chew E, Fanning MM, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988 157:569-72.
14. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988;25:339-49.
15. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
16. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
17. DeArmond B. Future directions in the management of cytomegalovirus infections. JAIDS, 1991;4(Suppl. 1):S53-S56.
18. Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients [letter]. AIDS 1992;6:515-6.
19. Studies of Ocular Complications of AIDS Research Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
20. Cacoub P, Deray G, Baumelou A, et al. Acute renal failure induced by foscarnet: 4 cases. Clin Nephrology 1988;29:315-8.
21. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989;9:316-21.
22. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and foscarnet effects on calcium and phosphorus metabolism. J Clin Endocrin Metabol 1991;72:1130-5.
23. Youle MS, Clarbour J, Gazzard B, Chanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine [letter]. Lancet 1988;1:1455-6.
24. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993;168:444-8.
25. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis. J Infect Dis 1991;163:1348-50.
26. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cylomegalovirus infection. J Infect Dis 1991;163:716-9.
27. Manischewitz JF, Quinnan GV, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990;34:373-75.
28. Freitas VR, Fraser-Smith EB, Matthews TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Research 1989;12:205-12.
29. Jacobson MA, Kramer F, Bassiakos Y, et al. Randomized phase I trial of two combination foscarnet/ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis (AIDS Clinical Trials Group Protocol 151). J Infect Dis 1994;170:189-93.
30. Dieterich DT, Poles MA, Lew EA. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993;167:1184-8.